US Patent

US9486428 — Treatment of intrahepatic cholestatic diseases

Method of Use · Assigned to CymaBay Therapeutics Inc · Expires 2035-03-19 · 9y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating intrahepatic cholestatic diseases using MBX-8025 or an MBX-8025 salt.

USPTO Abstract

Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.

Drugs covered by this patent

seladelpar-lysine (SELADELPAR LYSINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1854`	—	seladelpar-lysine

Patent Metadata

Patent number: US9486428
Jurisdiction: US
Classification: Method of Use
Expires: 2035-03-19
Drug substance claim: No
Drug product claim: No
Assignee: CymaBay Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.